ENTX Valuation
Entera Bio Ltd
$
2.030
- Overview
- Forecast
- Valuation
- Earnings
ENTX Relative Valuation
ENTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ENTX is overvalued; if below, it's undervalued.
Historical Valuation
Entera Bio Ltd (ENTX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 4305.40 is considered Overvalued compared with the five-year average of -4.02. The fair price of Entera Bio Ltd (ENTX) is between 0.18 to 1.25 according to relative valuation methord. Compared to the current price of 2.03 USD , Entera Bio Ltd is Overvalued By 62.9%.
Relative Value
Fair Zone
0.18-1.25
Current Price：2.03
62.9%
Overvalued
-3.81
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Entera Bio Ltd. (ENTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-2.94
EV/EBIT
Entera Bio Ltd. (ENTX) has a current EV/EBIT of -2.94. The 5-year average EV/EBIT is -2.57. The thresholds are as follows: Strongly Undervalued below -6.53, Undervalued between -6.53 and -4.55, Fairly Valued between -0.60 and -4.55, Overvalued between -0.60 and 1.38, and Strongly Overvalued above 1.38. The current Forward EV/EBIT of -2.94 falls within the Historic Trend Line -Fairly Valued range.
4196.68
PS
Entera Bio Ltd. (ENTX) has a current PS of 4196.68. The 5-year average PS is 570.60. The thresholds are as follows: Strongly Undervalued below -1166.06, Undervalued between -1166.06 and -297.73, Fairly Valued between 1438.93 and -297.73, Overvalued between 1438.93 and 2307.25, and Strongly Overvalued above 2307.25. The current Forward PS of 4196.68 falls within the Strongly Overvalued range.
0.00
P/OCF
Entera Bio Ltd. (ENTX) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.00. The thresholds are as follows: Strongly Undervalued below -8.14, Undervalued between -8.14 and -5.07, Fairly Valued between 1.07 and -5.07, Overvalued between 1.07 and 4.14, and Strongly Overvalued above 4.14. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Entera Bio Ltd. (ENTX) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.80. The thresholds are as follows: Strongly Undervalued below -8.46, Undervalued between -8.46 and -5.13, Fairly Valued between 1.53 and -5.13, Overvalued between 1.53 and 4.86, and Strongly Overvalued above 4.86. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Entera Bio Ltd (ENTX) has a current Price-to-Book (P/B) ratio of 4.46. Compared to its 3-year average P/B ratio of 5.29 , the current P/B ratio is approximately -15.70% higher. Relative to its 5-year average P/B ratio of 5.19, the current P/B ratio is about -14.07% higher. Entera Bio Ltd (ENTX) has a Forward Free Cash Flow (FCF) yield of approximately -7.41%. Compared to its 3-year average FCF yield of -25.82%, the current FCF yield is approximately -71.32% lower. Relative to its 5-year average FCF yield of -24.58% , the current FCF yield is about -69.87% lower.
4.46
P/B
Median3y
5.29
Median5y
5.19
-7.60
FCF Yield
Median3y
-25.82
Median5y
-24.58
Competitors Valuation Multiple
The average P/S ratio for ENTX's competitors is 742.38, providing a benchmark for relative valuation. Entera Bio Ltd Corp (ENTX) exhibits a P/S ratio of 4196.68, which is 465.30% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ENTX increased by 5.88% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -3.76K to -12.44K.
The secondary factor is the Revenue Growth, contributed -100.00%to the performance.
Overall, the performance of ENTX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Entera Bio Ltd (ENTX) currently overvalued or undervalued?
Entera Bio Ltd (ENTX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 4305.40 is considered Overvalued compared with the five-year average of -4.02. The fair price of Entera Bio Ltd (ENTX) is between 0.18 to 1.25 according to relative valuation methord. Compared to the current price of 2.03 USD , Entera Bio Ltd is Overvalued By 62.90% .
What is Entera Bio Ltd (ENTX) fair value?
How does ENTX's valuation metrics compare to the industry average?
What is the current P/B ratio for Entera Bio Ltd (ENTX) as of Sep 03 2025?
What is the current FCF Yield for Entera Bio Ltd (ENTX) as of Sep 03 2025?
What is the current Forward P/E ratio for Entera Bio Ltd (ENTX) as of Sep 03 2025?